Teva Settles On US Vivitrol Despite Conclusion Of Patent-Litigation Trial
Closing Arguments Heard In June; Alkermes Backs Brand Even With Potential Generic
Teva potentially was only a matter of days away from hearing a decision in its patent litigation battle over Vivitrol (naltrexone) long-acting injectable, but has instead put pen to paper on a settlement deal.
